1. P1053: ALBUMIN AND C-REACTIVE PROTEIN PROVIDE PROGNOSTIC INFORMATION INDEPENDENTLY FROM MIPSS70 IN OVERT MYELOFIBROSIS. A RETROSPECTIVE STUDY. (23rd June 2022) Authors: Messerich, N.-M.; Volken, T.; Cogliatti, S.; Lehmann, T.; Holbro, A.; Demmer, I.; Benz, R.; Jochum, W.; Silzle, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 943 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. (April 2019) Authors: Schmid, S.; Klingbiel, D.; Aeppli, S.; Britschgi, C.; Gautschi, O.; Pless, M.; Rothschild, S.; Wannesson, L.; Janthur, W.; Foerbs, D.; Demmer, I.; Jochum, W.; Früh, M. Journal: Lung cancer Issue: Volume 130(2019) Page Start: 149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION. (23rd June 2022) Authors: Koster, K.-L.; Messerich, N.-M.; Volken, T.; Cogliatti, S.; Lehmann, T.; Holbro, A.; Benz, R.; Graf, L.; Demmer, I.; Jochum, W.; Silzle, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗